Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Long-term Debt

Borrowings due after more than one year.

Citius Oncology, Inc.NASDAQ: CTOR

Long-term Debt · Q2 FY2026 · quarter ended Mar 2026

Long-term debt broadly unchanged from a year ago

Long-term debt stood at $3.8M at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.

Context

  • Long-term debt amounted to 3.8% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.8M+0.0% QoQ
Last fiscal yearSep 2025
$3.8M+0.0% YoY
Year agoMar 2025
$3.8M+0.0% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
3.8M USD
Year-over-year change
+0.0%

Long-term Debt vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's Mar 2026 long-term debt of $3.8M is the 3rd highest of the 10 companies compared; the peer median is $507K.
  • Its year-over-year change of +0.0% is the highest of 2, against a peer median of -49.3%.
  • Long-term debt amounts to 3.8% of total assets for CTOR, versus a peer median of 0.9%.
CTOR Competitors Peer median
Long-term Debt for CTOR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FATEFate Therapeutics, Inc.Mar 2026$72.05M ——25.3%
SCLXScilex Holding CompanyMar 2026$5.6M ——1.9%
CTORCitius Oncology, Inc.Mar 2026$3.8M +0.0%—3.8%
VORVor Biopharma Inc.Mar 2026$2.63M ——0.5%
OWLTOwlet, Inc.Mar 2026$1.95M -49.3%—2.2%
SPROSpero Therapeutics, Inc.Mar 2026$507K ——0.9%
ACTUActuate Therapeutics IncMar 2026$404.99K —+0.0%4.5%
FBRXForte Biosciences, Inc.Mar 2026$0 ——0.0%
LNSRLENSAR, Inc.Mar 2026$0 ——0.0%
MCRBSeres Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding CTOR) $507K-49.3%+0.0%0.9%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents001123.92M
Short-term Investments0000
Net Receivables0000
Inventory008.27M22.29M
Other Current Assets0000
Total Current Assets2.69M7.73M10.97M27.54M
Property, Plant & Equipment (Net)0000
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets40M40M73.4M73.4M
Total Non-current Assets40M40M73.4M73.4M
Total Assets42.69M47.73M84.37M100.94M
Account Payables92.31K1.29M3.71M13.23M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities0028.4M22.65M
Total Current Liabilities5.85M21.05M32.7M49.49M
Long-term Debt003.8M3.8M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities576K1.15M1.73M2.78M
Total Non-current Liabilities576K1.15M5.53M6.59M
Total Liabilities6.42M22.2M38.23M56.08M
Common Stock6.75K6.75K7.16K8.35K
Retained Earnings(5.43M)(18.13M)(39.28M)(64.04M)
Accumulated OCI0000
Other Stockholders Equity0000
Minority Interest0000
Total Equity36.27M25.54M46.14M44.87M
Total Debt003.8M3.8M
Net Debt003.8M(124.8K)

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.